Outcome measures | References* (country) | Study design | Birth weight | Gestational age | Number of participants | Type of feed | Osmolality/ osmolarity† | Osmolality/ osmolarity measured | Outcomes |
Gastric emptying | Pascale (1978)13 (USA) | RCT | <2000 g | Not reported | 8 | Intact protein formula (Isocal) | 204 mOsm/L | No | Greater delay in gastric emptying in infants fed higher osmolarity formula. |
6 | Intact protein formula (Portagen) | 211 mOsm/L | |||||||
13 | Hydrolysed protein formula (Pregestimil) | 539 mOsm/L | |||||||
Gastric emptying | Ramirez (2006)14 (USA) | Cross-over RCT | <1570 g | 25–30 weeks | 10 | Half strength human milk or formula‡ | 155 mOsm/kg | Yes | No change in gastric emptying with a higher diet osmolality. |
Half strength human milk or formula‡ | 310 mOsm/kg | ||||||||
Half strength human milk or formula‡ | 310 mOsm/kg | ||||||||
Full strength human milk or formula‡ | 310 mOsm/kg | ||||||||
7 | Full strength human milk or formula‡ | 155 mOsm/kg | Yes | Accelerated gastric emptying with decreased osmolality and increased feed volume. | |||||
Full strength human milk or formula‡ | 310 mOsm/kg | ||||||||
Gastric emptying | Siegel (1982)15 (USA) | Cross-over RCT | Not reported | 26–34 weeks | 10 | With sucrose (Neo-Mull-Soy) | 279±12 mOsm/kg | Yes | No significant difference in gastric emptying. |
With glucose (Cho-Free with glucose) | 448±11 mOsm/kg | ||||||||
Gastric emptying | Yigit (2008)16 (Turkey) | Cross-over RCT | 600–1470 g | Mean 29.8 weeks | 20 | Human milk | 319±19 mOsm/§ | Yes | No significant increase in gastric emptying time for full strength fortification. |
Half strength HMF (Eoprotin) | 365±25 mOsm/L§ | ||||||||
Full strength HMF (Eoprotin) | 440±44 mOsm/L§ | ||||||||
Tolerance; Gastric emptying | Kanmaz (2013)17 (Turkey) | RCT | ≤1500 g | ≤32 weeks | 26 | Standard fortification (Eoprotin) | 340 mOsm/L | No | No significant difference in feeding intolerance, residuals and abdominal distension. |
29 | Moderate fortification (Eoprotin) | 360 mOsm/L | |||||||
29 | Aggressive fortification (Eoprotin) | 380 mOsm/L | |||||||
Tolerance; Overall morbidity | Kim (2015) 18 (USA) | RCT | 700–1500 g | ≤33 weeks | 63 | Powdered intact protein HMF (Similac) | 385 mOsm/kg | No | No significant differences in overall morbidity, and both fortifiers were well tolerated. |
66 | New liquid hydrolysed protein HMF | 450 mOsm/kg | |||||||
Tolerance; NEC | Singh (2017)19 (India) | Prospective observational | <1500 g | Not reported | 15 | Higher carbohydrate HMF (Lactodex) | 378±34 mOsm/kg | Yes | No significant difference in episodes of feeding intolerance or NEC. |
15 | Higher fat HMF (HIJAM) | 420±31 mOsm/kg | |||||||
15 | Higher carbohydrate HMF (FM-85) | 451±39 mOsm/kg | |||||||
Tolerance; NEC | Rigo (2017)20 (France, Belgium, Germany, Switzerland and Italy) | RCT | ≤1500 g | ≤32 weeks | 76 | New partially hydrolysed protein HMF (with higher protein and micronutrients) | 390 mOsm/kg | Yes | No significant difference in feeding tolerance and NEC. |
74 | Extensively hydrolysed protein HMF (FM-85) | 441 mOsm/kg | |||||||
NEC | Book (1975)21 (USA) | RCT | <1200 g | 24–32 weeks | 8 | Cow milk formula (premature formula) | 359 mOsm/L | No | Significantly higher incidence of NEC in the elemental formula group (87.5%) compared with cow milk formula group (25%). |
8 | Elemental formula (Pregestimil) | 650 mOsm/L | |||||||
NEC | Thoene (2016)22 (USA) | Retrospective observational | <2000 g | Not reported | 23 | Acidified liquid hydrolysed protein HMF | 326 mOsm/kg | No | Significantly higher incidence of NEC in the feed group with lowest osmolality. |
46 | Powdered intact protein HMF | 385 mOsm/kg | |||||||
51 | Non-acidified liquid intact protein HMF | 385 mOsm/kg |
*References indicated with first author and year.
† Osmolality/osmolarity values were rounded up.
‡Formula used in Ramirez et al 14 were either Enfamil 24 or Neosure.
§Range of values also reported in Yigit et al 16 (275–371 mOsm/L, 310–411 mOsm/L and 344–576 mOsm/L).
HMF, human milk fortifier; NEC, necrotising enterocolitis.